Skip to main
SMTI
SMTI logo

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech has demonstrated significant growth in its surgical and soft tissue repair product segments, with sales increasing 24% year-over-year to $23.4 million, primarily driven by the demand for CellerateRX Surgical Activated Collagen. Additionally, the company’s strategic focus on expanding its distribution network and increasing penetration in healthcare facilities is expected to further enhance topline growth. With revenue projections for the upcoming 12 months showing positive trends, continuing operations are anticipated to become profitable by the third quarter of 2025.

Bears say

Sanara MedTech Inc. reported net revenue of $26.3 million, indicating a year-over-year growth of 21.5%, which fell slightly short of expectations of $26.7 million. The company faces several substantial risks that contribute to a negative financial outlook, including lower-than-expected revenue growth, challenges in acquiring new customers, delays in product launches, and potential dilution of shareholder value. Additionally, the company has decreased its enterprise value to revenue multiple from 4.3x to 3.0x, reflecting the removal of telehealth from its business strategy and suggesting concerns regarding its future revenue-generating potential.

SMTI has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Buy based on their latest research and market trends.

According to 2 analysts, SMTI has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.